Display Settings:

Format

Send to:

Choose Destination
    Neuropsychiatr Dis Treat. 2009;5:279-88. Epub 2009 May 20.

    Treatment and prevention of mania in bipolar I disorder: focus on aripiprazole.

    Source

    Center for Mood Disorders Treatment and Research, Cleveland Clinic Neurological Institute, Cleveland, Ohio, USA. muzinad@ccf.org

    Abstract

    Aripiprazole is a second-generation antipsychotic with a unique pharmacologic receptor profile that has efficacy in the treatment and prevention of mania in bipolar I disorder. This article reviews the evidence supporting treatment of adults with bipolar I disorder using aripiprazole as monotherapy or adjunctively during acute mania and its utility as an intramuscular agent for agitation in manic patients. Results from one of the longest bipolar maintenance trials which support aripiprazole as a prophylactic mood stabilizer, specifically against manic relapses, will be discussed as well as a post-hoc analysis that suggests efficacy for rapid cycling bipolar disorder. Safety and tolerability issues, patient-focused perspectives and aripiprazole's place in therapy for bipolar mania will be covered.

    PMID:
    19557122
    [PubMed]
    PMCID:
    PMC2695233
    Free PMC Article

    Images from this publication.See all images (2) Free text

    Figure 1
    Figure 2

      Supplemental Content

      Icon for Dove Medical Press Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk